Anti-PM-S& antibodies are associated with polymyositisscleroderma overlap or either disease alone. Among sera from 39 patients with anti-PM-S&, 23 recognized the 100-kD band in immunoblot against HeLa cell extract, 16 of which also stained the 70-kD band. A human thymocyte Xgtll cDNA expression library was screened with anti-PM-S& serum, and two clones were identified whose products reacted with 33 and 37 of 39 anti-PM-Sd sera, respectively, but none of 26 negative control sera. Affinity-purified antibody reacting specifically with plaques of the clone stained the 100-kD band on immunoblot, reacted with nucleoli of HEp-2 cells, and immunoprecipitated the PM-Sd protein complex. Partial sequences of both inserts were identical. One insert was fully sequenced, and additional 5' and 3' sequence was obtained using a gene-specific primer to form a cDNA with HeLa cell RNA as template followed by PCR. The complete nucleotide sequence included 2,739-bp coding for a predicted full-length protein of 98,088 D. There was no homology with the PM-Scl 75-kD protein and no significant homology with other proteins. A mixed-charge cluster was identified, with 22 charged amino acids of37. In conclusion, the full-length cDNA sequence was determined coding for the PMScl 100-kD protein, the most commonly antigenic protein ofthe PM-Scl complex. (J. Clin. Invest. 1992. 90:559-570.)
Introduction
Autoantibodies reacting with the PM-Scl antigen have been found in sera from patients with polymyositis or scleroderma or from patients with overlap of these two conditions (1) (2) (3) (4) (5) . They were identified in 8% of a large group of myositis patients and -3% of a group of scleroderma patients ( 1, 4).
However, it is very rare for this antibody to be found in patients with other conditions, making it a valuable disease marker, and suggesting that it may have links to fundamental disease mechanisms in those patients in whom it is found. Anti-PM-Scl is the unique specificity derived from anti-PM-l ( 1, 6) .
The PM-Scl antigen is found in the nucleolus (7, 8) , and all sera with anti-PM-Scl stain the nucleolus in indirect immunofluorescence. Most sera with the antibody also stain the nucleus, but antibody could be affinity purified that reacted only with the nucleolus (7) . The role of the antigen in cell physiology is not known, but it may be involved in preribosomal formation, a function of the nucleolus, since compounds that interfere with ribosomal formation also interfere with its production (8) .
Immunoprecipitation of35S-labeled HeLa cell extracts with anti-PM-Scl shows a group of 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] proteins that appear to be a complex (8, 9) . A prominent band is seen at 100 kD, but bands are present from 20 to 110 kD. No nucleic acids have been associated with the antigen by immunoprecipitation. Most sera with the antibody react with a 100-1 10-kD protein in immunoblot studies (9) , and some also react with a second protein migrating in the range of 70-75 kD (10) . Occasional sera react primarily with this second protein. The gene encoding the second protein has recently been cloned and sequenced and has been found to produce a protein of 39.2 kD that migrated aberrantly on PAGE, apparently because ofa region rich in acidic residues in the carboxyl halfofthe molecule ( 10). The 100-1 0-kD protein that is commonly antigenic has not been analyzed in detail. To study further the larger antigenic protein ofthe PM-Scl antigen on a molecular level, we have isolated a complementary DNA (cDNA) ' that codes for this protein and have determined its sequence.
Methods
Sera. Sera were drawn from clinical screening at the Oklahoma Medical Research Foundation or from sera referred for testing for myositisassociated autoantibodies. Sera from 39 patients were found to contain anti-PM-Scl by immunodiffusion and confirmed by immunoprecipitation. 20 myositis sera from this collection found to be negative for anti-PM-Scl were tested as controls, some ofwhich had other autoantibodies. Six sera from healthy laboratory workers were also tested.
Immunoblotting. Each serum was tested by immunoblotting against whole HeLa cell lysate as antigen source to determine its component reactivity. Antibodies that were affinity purified from Escherichia coli-expressed PM-Scd fusion protein as below were tested against whole HeLa cell lysates or against immunoprecipitates prepared with anti-PM-Scl serum from HeLa cell lysates. The size ofthe PM-Scl molecules expressed in E. coli were also determined with immunoblot assays against E. coli lysate containing the recombinant protein.
The HeLa lysate was prepared by sonication in 0.15 M NaCl in 0.05 M Tris-HCI buffer at pH 7.4 whereas E. coli lysates were prepared by lysis with Xgtl 1 bacteriophage with or without the cloned insert or with the sample buffer containing SDS for use in electrophoresis ( 11) . The lysates and immunoprecipitates were electrophoresed in 10% SDS-PAGE and blotting was carried out as previously described ( cept that 8% nonfat milk was used for blocking. Sera were diluted 1:100 for routine testing, and affinity purified antibody was used undiluted.
Isolation ofPM-Scl cDNA. It was previously known that the PMScl antigen was present in thymus tissue by immunodiffusion against calfthymus extract ( I ) and in HeLa cells by immunoprecipitation (8) . Therefore, human thymocyte cDNA and HeLa cell cDNA Xgtl 1 expression libraries from Clontech Laboratories (Palo Alto, CA) were screened. Serum from patient J.H. with diffuse scleroderma, shown to contain anti-PM-Scl by immunodiffusion and to react with both the 100-and 70-kD proteins by immunoblotting, was used for screening, diluted 1/500 in 0.05 M Tris buffer at pH 8.0 with 0.15 M NaCl and 0.05% Tween-20 (TBST) with 2% BSA and 10 mM sodium azide. Recombinant phage were plated with E. coli Y1090 on LB agar, incubated at 42°C for 3-4 h, overlayered with nitrocellulose membranes soaked in isopropylthio-(3-galactoside (IPTG), and incubated for another 3 h at 370C. The membranes were then washed, blocked, incubated with diluted patient serum, and developed as for immunoblotting, using alkaline-phosphatase-coupled anti-human IgG conjugate and 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium substrate. A total of 2 X 106 plaques from each of the libraries were screened. Positive clones were plaque purified.
Affinity purification ofantibodies. Specific antibodies were affinity purified by elution from proteins derived from plaques ofthe recombinant PM-Scl bacteriophage. To reduce the background attributable to anti-E. coli antibodies, sera were first preabsorbed with nitrocellulose membranes coated with proteins from E. coli that had been lysed with wild-type Xgtl 1 bacteriophage as described above. LB plates were prepared with a high concentration ofeither plaque-purified recombinant PM-Scl bacteriophage or wild-type bacteriophage. The plates were overlaid with IPTG-soaked nitrocellulose membranes, which were then incubated with absorbed anti-PM-Scl or other serum overnight at 40C, as described above for screening. After five TBST washes, membrane-bound antibodies were eluted with 0.2 M glycine-HCl at pH 2.5 for 1.5 min. Collected eluates were neutralized immediately by adding 1 M Tris base. The activity of the affinity-purified antibody was confirmed by testing against recombinant and wild-type bacteriophage proteins on nitrocellulose as above.
Testing of patient sera. To determine whether patient sera with anti-PM-Scl or controls reacted with the protein product of the clone, plaque-purified recombinant bacteriophage were mixed 5:1 with wildtype Xgtl 1 and plated with E. coli Y1090, as for screening. Pieces of nitrocellulose carrying plaque proteins were incubated with 5 ml of an individual serum diluted 1:600 and developed. Reactions were considered positive if significant staining of -20% of the plaques was seen. Intensity of staining was estimated on a 0 (negative) to 4+ (strongest) scale. Three anti-PM-Scl and two normal sera were also tested against IPTG-induced E. coli lysed with recombinant bacteriophage in immunoblot as described above.
Immunoprecipitation. Immunoprecipitation from "S-methionine-labeled HeLa cell lysate was performed as previously described (12) . 1 mg protein A-Sepharose (Pharmacia LKB, Uppsala, Sweden) ( 10 Ml of swelled bead suspension) was coated with 20 Ml of serum or 500 Al of affinity-purified antibody. Immunoprecipitates were analyzed on 10% SDS-PAGE. Preparation of unlabeled immunoprecipitates for immunoblot analysis of affinity-purified antibodies was similar but the immunoprecipitates were treated as for protein analysis. Immunoprecipitation from unlabeled HeLa cell lysate for nucleic acid analysis was also performed as previously described ( 12) . One 150-cm2 flask of HeLa cells was used for three samples. 4 mg of protein-A-Sepharose were coated with 20 Al of serum. Phenol-extracted immunoprecipitates were analyzed on 7 M urea, 10% PAGE, and developed with silver stain (Bio-Rad Laboratories, Richmond, CA).
Northern blot analysis. Total RNA was isolated from HeLa cells by the procedure of Chomczynski and Sacchi (13) , and poly-(A)' RNA was isolated from HeLa cells using a commercial kit (MicroFastTrack; Invitrogen, San Diego, CA). Both were electrophoresed in a denaturing 1% agarose gel containing 2 M formaldehyde and were transferred onto Nytran membrane (Schleicher & Schuell, Inc., Keene, NH) ( 14) . Prehybridization with salmon sperm DNA and hybridization with radiolabeled cDNA probe (15, 16) were performed in 2x prehybridization and hybridization buffers from 5 Prime-3 Prime Inc. (Boulder, CO) according to their instructions, with formamide at 420C. Membranes were washed under high stringency conditions with 0.1 X standard saline citrate and 0.1% SDS at 650C for 30 min and were developed with autoradiography.
DNA sequencing. DNA from the plaque-purified recombinant Xgtl 1 bacteriophage was prepared from liquid lysates and digested with EcoRI to excise the cDNA insert. The insert was isolated by fractionation in an agarose gel and subcloned into the plasmid pUCl 8 (17) . After restriction enzyme mapping of the cDNA, individual restriction fragments were isolated from agarose gels. These were ligated into M I 3mpl 8 and mpl9 (17) and were used to transform E. coli strain XLl Blue. The complete nucleotide sequences of both strands of the cDNA were determined by using the dideoxynucleotide chain-termination method ( 18) Bold sequences were added for restriction enzyme sites. Numbered regions correspond to sequence shown in Fig. 9 restriction-site adapter. The primer used was different from that used for first-strand cDNA synthesis in order to increase the specificity for this gene and avoid amplification of tailed first-strand primer. The cDNA template was denatured at 950C for 5 min followed by chilling on ice. It was centrifuged briefly, and then 2.5 U ofTaq DNA polymerase (Promega Corp.) and two drops of mineral oil were added. A total of 35 cycles were performed, consisting of 940C for 50 s, 540C for 1 min, and 720C for 1 min, with a final elongation step at 720C for 5 min. The 3' end was amplified by a similar procedure. Total RNA and poly-(A)' RNA from HeLa cells were reverse transcribed using an oligo-d(T) primer. After RNAse digestion, the deoxynucleotide triphosphates were removed by using a G-50 spin column (5 Prime-3 Prime Inc.). The 3' end was amplified from the cDNA pool in a PCR using gene-specific primer 3 (Table I ) and the oligo-d(T) primer.
The 5' and 3' extended cDNA products were analyzed by electrophoresis in 8% PAGE. To confirm that the products were specific, Southern blotting was performed (22), in which the gel products were electroblotted onto Hybond-N membrane (Amersham Corp., Arlington Heights, IL), and hybridization was performed with a 32P-labeled cDNA insert as probe. Specific products were isolated from the gel by diffusion ( 14) . A portion ofthe products were subcloned into the plasmid vector pUC 18 after digestion ofthe 5' products with PstI and Bgl II, or digestion ofthe 3' products with XbaI and PstI. Other PCR products were subcloned into the plasmid vector PCR1000 (Invitrogen) according to manufacturer's instructions without previous treatment. All extended products were sequenced from a double-stranded DNA template with T7 DNA polymerase (Pharmacia LKB) as above.
Expression of the recombinant protein. Expression of the protein coded for by the sequence including the extended 5' end was achieved from a new cDNA prepared by reverse transcription from total HeLa 
All 39 sera were positive for anti-PM-Scl by immunodiffusion and were tested for reaction with the 100-and 70-kD bands on immunoblot against whole HeLa cell extract. Reaction in immunoblot was assessed as positive (+) or negative (-), whereas positive reaction against the two JH4 clones was estimated as 1+ through 4+. Other refers to reaction in immunoblot with bands other than the 100-and 70-kD bands. cell RNA using an oligo-d(T) primer, followed by PCR amplification using gene-specific primer 4 (Table I) (23), using a VAX 8250 computer, and also using a supercomputer through the Pittsburgh Supercomputing Facility as previously described (24) . Tests for charged runs and clusters in protein sequences were performed using the PROPAT program (25) 
Results
Immunoblotting. The 39 sera identified as positive for anti-PM-Scd were tested by immunoblotting against whole HeLa cell extract to determine the antigenic proteins for each serum (shown for 13 patient sera in Fig. 1 ). 23 sera (59%) stained a l00-kD band, and 16 of these 23 sera (41% of total) also stained a 70-kD band (Tables II and III) . Only 1 serum stained the 70-kD band and not the 100-kD band, although 1 ofthe 23 that stained the l00-kD band stained the 70-kD band much more strongly. The 70-and 100-kD bands appeared to correspond to the 75-and 1 0-kD bands reported by others (9, 10) . The 100-kD band appeared as a doublet in some runs, apparently due to degradation of the lOO-kD band since the second band was not consistently present. 21 sera recognized bands other than the 100-and 70-kD bands, 6 ofwhich were negative against the 100-and 70-kD bands. Among the other bands, bands of 30-and 32-kD were seen with 2 sera (K and M in Fig.  1) ; a 50-kD band with 3; and a weak, inconsistent 85-kD band with 10, which was similar to a band reported by others (10) . Other bands were unique to individual sera. Nine sera had negative immunoblots. Staining of the 100-and 70-kD bands by all positive sera was weak in each of the several runs performed, even by sera with high anti-PM-Scl titers, but some of the other bands were stained strongly. The relationship of the other bands to the PM-Scl antigen complex remains unclear. :..
-, tion with JH serum were negative against the plaques of both clones.
Affinity-purified antibody from JH serum using clone JH4B1 stained a 100-kD protein in immunoblotting against whole HeLa cell extract, similar in size to the 100-kD protein stained by whole JH serum (Fig. 4) . However, other proteins stained in immunoblotting by whole JH serum, including the 70-kD protein, were not seen with affinity-purified antibody. Wild-type eluates were negative in immunoblotting.
Further testing was performed to determine whether this result was typical of other anti-PM-Scl sera. Anti-PM-Scl immunoprecipitates from HeLa cell extract prepared using JH serum were used as antigen rather than whole HeLa cell extract. Whole JH serum recognized a 100-kD doublet and the 70-kD band whereas affinity-purified antibody from JH serum recognized only the 100-kD doublet (Fig. 5 ). After incubation with JH4B1 plaque proteins, staining ofthe 100-kD doublet by JH serum was substantially decreased but staining ofthe 70-kD band was not. Antibody was similarly affinity purified from four of the other anti-PM-Scl sera that had reacted with both the 100-and 70-kD bands, using both JH4B, and wild-type Xgt I 1. In each case, the affinity-purified antibody from the JH4 clone reacted with the 100-kD doublet of the immunoprecipitate but not the 70-kD band. The wild-type eluates were all negative (Fig. 5) .
JH serum antibodies affinity purified from the JH4B, clone were also found to stain the nucleoli ofHEp-2 cells, in a pattern similar to that seen with whole JH serum (Fig. 6 ) whereas wild-type eluates were negative. Affinity-purified antibody was also active in 35S-immunoprecipitation. In addition to the 100-kD band, affinity-purified antibody immunoprecipitated the smaller bands (under 40 kD) typical of the immunoprecipitation pattern of anti-PM-Scl sera, apparently due to their affinity for the 100-kD band as part ofthe PM-Scl complex (Fig. 7) . Antibody eluted from wild-type plaques also showed this pattern, apparently because ofbackground binding ofpatient antibody to the plaques, but it was much weaker than that seen with antibody eluted from the clone. These studies indicated that anti-100-kD anti-PM-Scl antibodies reacted with the protein expressed by the JH4 clones. Sequencing ofPM-Scl cDNA. The DNAs of clones JH4B1
and JH4C, were digested with EcoRI. Agarose gel electrophoresis ofthe products showed a similar sized single insert of -2.5 kb for each clone. Inserts from both clones were subcloned into the EcoRI site of pUC18. Partial sequencing from the doublestranded plasmid DNA showed that both clones had identical terminal sequences.
A restriction map of the JH4B, insert was obtained by single and double digestions with selected restriction enzymes (Fig. 8) . Four fragments were obtained by digestion with KpnI and TaqI, and three fragments were obtained following SmaI digestion. All seven fragments of JH4B1 were then isolated from agarose gels, subcloned into Ml 3mp18, and sequenced. Subclones from each of these strategies were used to verify the positions of the five restriction sites shown in Fig. 8 . The sequence of both strands of the JH4B1 insert was thus determined. Including EcoRI linkers (not shown), it contained 2,479 nucleotides, with a single long open-reading frame of 2,331 nucleotides from the first ATG codon at position 288 in Fig. 9 to a stop codon at position 2,619. The predicted protein from the insert cDNA included 777 amino acids, with a predicted molecular mass of 89 kD, smaller than the observed mass of the antigenic protein in this study (100 kD) or that reported in other studies (110 kD). No poly-(A) tail was detected in the cDNA insert.
Northern blot analysis. Northern blot against both total RNA and poly-(A)' RNA from HeLa cells showed hybridization of32P-labeled JH4B, cDNA insert with a single band of2.7 kb (Fig. 10) (not shown). This indicated that the JH4 cDNA inserts, at Determination ofthe 'and3'ends ofthefull-length cDNA. < 2.5 kb, included most but not all of the full length of the The ends of the cDNA were extended and amplified as decorresponding mRNA. showed a predominant band ranging from 320 to 340 bp, whether total or poly-(A)' RNA was used for the template for cDNA synthesis. In some PCR amplifications using the same cDNA as template, analysis of the products showed multiple bands in addition to the predominant 340-bp band. However, after electroblotting of electrophoresed PCR products onto a nylon membrane, only the 340-bp band hybridized with 32P-labeled JH4B, insert.
To identify the longest extensions present, a range of products were isolated from the polyacrylamide gel by diffusion. Aliquots of PCR products were subcloned into pUC18 or PCR1000 (see Methods). 19 subclones were obtained and 11 were selected and sequenced from plasmid mini-preps. These 11 were derived from 5 different PCRs that were performed using cDNA pools from three reverse transcription reactions. The sequences showed that all of the clones started from the gene-specific primer, contained the 88 bp of known sequence from the JH4B, cDNA (discounting the EcoRI linker), extended 180-210 nucleotides beyond the 5' end of the cDNA, and then showed the poly-(T) expected from the tailing reaction. The first initiation codon of the maximum-length-extended 5' portion was at position 39 (Fig. 9) , outside the original cDNA. All putative translational starting site, which differed from that predicted from the initial cDNA insert by 249 nucleotides (83 amino acids). None of these subclones contained an in-frame stop codon upstream of the first ATG. Two slight discrepancies were noted among the 11 sequenced 5' extensions: 1 of 11 showed a change from a T to a C at position 96 of the 5' extension whereas another showed a change from a G to an A at position 191. Although it is possible that one of these represents a different allele, their low frequency suggests that they more likely represent mutant Taq polymerase products.
Although a stop codon was present in the open-reading frame ofthe cDNA insert (Fig. 9, position 2,619) , the poly-(A) tail was not present, and therefore the 3' end was amplified as well. PAGE of PCR amplification products ofthe 3' extensions showed a predominant band at 180 bp, but multiple other bands were identified. Southern blotting and hybridization with a 32P-labeled cDNA insert, however, showed hybridization only with the 180-bp band. An aliquot of PCR products was digested with XbaI and PstI and subcloned into pUC18 and PCR1000. Eight subclones were selected for sequencing. The sequences ofall ofthe clones started from the gene-specific primer 99 bp upstream from the 3 (Fig. 11) . The mobility of the E. coli-expressed protein in PAGE was slightly larger, by -2-4 kD, than the native HeLa cell immunoprecipitated 100-kD protein.
Analysis ofthefull-length sequence. The full-length nucleotide sequence of this PM-Scl gene including the extended 5' and 3' ends was 2,739 bp long. This sequence consists of 38 nucleotides in the 5' untranslated region, 2,580 bp in the predicted coding region from the first methionine codon, and 100 nucleotides from the stop codon up to the 21 nucleotide poly-(A) tail (Fig. 9) . The deduced amino acid sequence was composed of 860 residues with a predicted molecular mass of 98,088 D, very close in size to the observed relative molecular weight in PAGE of the PM-Scl 100-kD antigen.
Several possible sites ofposttranslational modification were observed. Two potential N-glycosylation sites were identified at residues 353 and 839. A number of potential phosphorylation sites were identified, including those for protein kinase C (at residues 849, 823, and 846), casein kinase II (at residues 18, 104, 292, 293, 333, 370, and 665), and tyrosine kinase (at 523). There were also amidation sites identified at residues 163 and 823. However, the presence ofthese sites does not necessarj4-HeIa-*I [4 - ily indicate that posttranslational modification occurs at these sites, and they are often observed in proteins that are not modified. There has been no evidence of posttranslational processing of the PM-Scl 100-kD protein reported.
One report indicated that a number of lupus and scleroderma autoantigens showed a higher frequency than other proteins ofcharge runs (a long series ofconsecutive charged amino acids) and charge clusters (a high frequency of charged amino acids, not necessarily consecutive, within a given stretch of amino acids) (25) . Although no charge runs were observed in this PM-Scl protein, a "mixed charge cluster" (consisting of both positive and negative residues) was found between residues 753 and 789, with 14 positive and 8 negatively charged residues among 37 amino acids, for a total of 59% charged amino acids within this region.
There was no significant homology with the sequence ofthe 75-kD PM-Scl protein (10) , and there were no sequences of more than four consecutive amino acids shared between the two proteins. Independence ofthe two major PM-Scl antigenic proteins on the amino acid level is consistent with the observation noted above that they were antigenically independent, since affinity-purified JH4B, eluates stained the 100-kD pro- 
Discussion
In this study, the full-length nucleotide and predicted amino acid sequence for the 100-kD antigenic protein of the PM-Scl antigen was determined. The l00-kD protein was found to be antigenic for the great majority of patients with anti-PM-Scl antibodies, even ifno activity was seen on routine immunoblotting. This protein appears to be independent ofthe 70-kD protein immunologically, consistent with the lack of primary amino acid sequence similarity between their predicted polypeptides.
Strong support was obtained for the conclusion that the cloned cDNA encodes a protein that reacts with anti-PM-Scl antibodies. First, extensive serum testing demonstrated that reaction with recombinant protein was specific for sera with anti-PM-Scl. No reaction was seen with sera containing other autoantibodies or normal human sera. Second, the affinitypurified antibodies that reacted with the fusion protein demonstrated similar specificity to that of antibodies to the 100-kD PM-Scl protein. The Evidence was also provided to support the conclusion that the cDNA codes for the same l00-kD PM-Scl protein that is part of-the immunoprecipitated PM-Scl antigen complex. The size ofthe expressed recombinant protein and the immunoprecipitated antigenic protein were shown to be similar. Affinitypurified antibodies recognized the l00-kD protein immunoprecipitated from HeLa cell extract by anti-PM-Scl sera. However, the possibility that the cDNA codes for a separate PM-Scl 100-kD protein that cross-reacts with the 100-kD antigenic protein of the immunoprecipitated PM-Scl complex has not been unequivocally excluded, since direct amino acid sequence of the protein was not available. Of interest was that in some cases, anti-PM-Scl sera stained a doublet at 100 kD in immunoblotting. The two forms of this protein shared epitopes since both reacted equally with affinity-purified antibodies. This may represent a degradation product as suggested by its intermittent appearance but other possibilities, such as a difference in posttranslational modifications, or, less likely, two different but closely related proteins, cannot be excluded. There is also strong support for the conclusion that this is the full length ofthe cDNA sequence. The mRNA detected by Northern blot was the same size as the original cDNA plus the extended ends. The predicted protein from the sequence is within 2% of the estimated molecular weight (100 kD) of the native antigenic PM-Scl protein observed by SDS-PAGE. The recombinant protein appeared even larger than the immunoprecipitated protein probably because ofdifferences in processing or posttranslational modifications. Others have reported the protein to be 1 10 kD. If 1 10 kD is the true physical molecular mass, the difference in size from the predicted protein may result from posttranslational modifications at one ofthe potential sites identified above. The sequence preceding the first ATG is consistent with commonly observed starting sites in that an A is present in the third position before the ATG whereas it is usually not found in the unusual event ofan ATG codon upstream of the starting ATG (26) . There is no A three nucleotides upstream to the second ATG, which is found within the original insert, suggesting it was not the starting site. Supporting the identification ofthe 3' end, a clear stop codon is present and the extended end contains the expected poly-(A) tail. Although the most common polyadenylation signal is AATAAA, ATTAAA is a recognized naturally occurring variant found in 12% of mRNAs and provides almost as much polyadenylation activity as the AATAAA signal (27) .
Although the 100-kD protein was the protein most commonly recognized by anti-PM-Scl positive sera in immunoblotting against whole HeLa cell extract, reaction was not seen with sera from 41% of patients with anti-PM-Scl. Although Gelpi et al. (9) found that all of 10 anti-PM-Scl sera reacted with the 1 I0-kD protein, Alderuccio et al. (10) found results similar to ours, with only half of anti-PM-Scl sera reacting in immunoblot against the 100-110-kD protein. However Anti-PM-Scl is an example in which a protein complex is targeted by autoantibodies. As demonstrated in this and other studies, antibody to the 100-kD protein is the most common specificity found. This suggests that the 100-kD band may be the main target ofthe anti-PM-Scl response. However, reaction with at least one other complex component is commonly seen, that of 70-75 kD. In this study, specific antibodies reacting with the 100-kD protein in immunoblot did not cross-react with the 70-kD protein. Others have also found that antibodies to the two proteins are independent (10). Independent reaction with multiple components suggests that the complex as a whole has become antigenic, which supports the antigen-driven nature of the autoantibody response. It is possible that some ofthe other protein bands recognized by anti-PM-Scl sera in immunoblotting are also complex components.
Preliminary results of Bluthner et al. (28) , presented in abstract form, described cDNA cloning of a small portion of the PM-Scl 100-kD protein and indicated that all anti-PM-Scl sera reacted with that small portion, suggesting a predominant epitope. The sequence of that fragment has not yet been published, and we are therefore not able to compare it to our sequence. Identification of the location of the epitopes of the PM-Scl 100-kD protein will be facilitated by the availability of the full-length sequence determined in this study. Analysis of the sequence did not reveal motifs that might suggest a specific function, but the availability of this recombinant protein will assist in further studies ofthe cellular function and cell biology of PM-Scl.
